Journal of Pharmacological and Toxicological Methods
Original articleTroubleshooting methods for APP processing in vitro
Introduction
Alzheimer's disease (AD) is a neurodegenerative disorder whose main pathological hallmarks are the presence of neuritic plaques, of β-amyloid peptide (Aβ), and neurofibrillary tangles, of hyperphosphorylated Tau. Although there is still no clear connection between both of these cerebral lesions, a great deal of evidence suggests that Aβ deposition could be the primary event. This hypothesis is known as the “amyloid hypothesis” (Walsh and Selkoe, 2004). Therefore, many of the studies related to AD have focused their attention on the regulation of Aβ generation.
Aβ is generated from the cleavage of a larger protein called Amyloid Precursor Protein (APP), which is alternatively cut by two enzymes called β-secretase also called BACE (from beta-APP cleaving enzyme) and γ-secretase. Alternatively, Aβ production can be eluded if APP is cleaved by an α-secretase (see reviews, Jacobsen & Iverfeldt, 2009, Sastre et al., 2008). Several proteins from the ADAM family have been implicated in this α-secretase cleavage, such as ADAM10 and ADAM17 (see review Sastre et al., 2008). The secretases are located in different cellular compartments. α-secretase cleavage and some γ-secretase cleavage of APP take place at the plasma membrane, while β-secretase activity is mainly localized in late endosomes. Therefore, a way to regulate Aβ generation is by modifying APP subcellular distribution. APP is processed through the secretory pathway, during which it is glycosylated and phosphorylated. APP can be also ubiquitinated and degraded by the proteasome (see review Jacobsen and Iverfeldt, 2009).
There are several forms of Aβ but the most common are Aβ1-40 and Aβ1-42, the latter being the most toxic and fibrillogenic. Aβ is physiologically secreted and can be found in physiological fluids such as blood and CSF as well as in tissue culture media from various cell types. In addition, there have been a large number of studies on post-mortem AD, Down syndrome and transgenic mouse brains which have revealed the presence of intracellular Aβ within neurons (see review LaFerla, Green, & Oddo, 2007), most of which has been found to be of the 1–42 subtype, and not 1–40 (Gouras et al., 2000). Furthermore, immunogold electron microscopy has been carried out to demonstrate that Aβ42 can be found in multivesicular bodies (MVBs) of neurons in the human brain, where it is associated with synaptic pathology (Takahashi et al., 2002). Recently longer intracellular Aβ forms have been detected, which seem to be the precursors of Aβ40 and 42, such as Aβ43, Aβ45, Aβ46, and Aβ48 (Qi-Takahara et al., 2005).
As seen in Fig. 1A, proteolysis of APP by α-secretase or β-secretase leads to the secretion of α-APPs (which has neurotrophic properties) or β-APPs respectively. Both secretases generate C-terminal fragments of 10 kDa and 12 kDa respectively, which are localized within the membrane (see review Walter, Kaether, Steiner, & Haass, 2001) (Fig. 1A). These fragments can be cut by the γ-secretase to release the peptides P3 and Aβ as well as a cytoplasmic fragment identified as the APP intracellular domain (AICD). This site is similar to the S3 cleavage site for Notch and was named ε-site (Weidemann et al., 2002). Recently, a new cleavage site was described for γ-secretase (Sastre et al., 2001). The ξ-cleavage occurs between the γ- and ε-cleavage sites and generates longer Aβ forms within cells and in the brain, including Aβ43, Aβ45, Aβ46, and Aβ48 (Qi-Takahara et al., 2005, Zhao et al., 2004).
Aβ can be degraded by different systems, which include enzymatic degradation or receptor-mediated clearance (Tanzi, Moir, & Wagner, 2004). Several peptidases have been identified, which are able to degrade soluble Aβ, such as the Insulin degrading enzyme (IDE) and neprylisin. In addition, Aβ can be cleared via phagocytosis by activated microglia and by transport through the blood–brain barrier. This process can be enhanced by binding to chaperons such as ApoE and α2-macroglobulin.
Therefore, studying APP processing provides information about the mechanisms by which Aβ levels are modified by a factor or treatment. In this paper, we give some tips how to analyse the processing of APP, using different methodology.
Section snippets
Problem 1: how to determine Aβ
There are several methods to determine Aβ present in tissue culture medium and in the supernatant of cell and tissue homogenates. These include ELISA, Western blotting, metabolic labelling and mass-spectrometry. In general, all these methods require the use of media and extracts from cells permanently transfected with APP, with high levels of overexpression, as natural expression levels are generally below the detection limits of currently available methods. The most widely cell lines used for
Discussion
The generation of Aβ has been considered for years a critical step for the development of dementia and Alzheimer's disease. The most important prediction of the amyloid hypothesis has been backed by the fact that decreasing Aβ load leads to an improvement of the symptoms of the disease, which has been recently achieved in experiments immunizing mice against Aβ by observing amelioration in behaviour (see review Hardy, 2009). Therefore, the potential of techniques that allow the detection and
Acknowledgements
I would like to thank Glenda Gillies and Callum Parr for critical reading of the manuscript.
References (44)
- et al.
Impairments in learning and memory accompanied by neurodegeneration in mice transgenic for the carboxyl-terminus of the amyloid precursor protein
Brain Research Molecular Brain Research
(1999) - et al.
Maturation and pro-peptide cleavage of beta-secretase
Journal of Biological Chemistry
(2000) - et al.
Intraneuronal Abeta42 accumulation in human brain
American Journal of Pathology
(2000) - et al.
Electrophoretic separation of betaA4 peptides (1-40) and (1-42)
Analytical Biochemistry
(1996) - et al.
Evidence that production and release of amyloid beta-protein involves the endocytic pathway
Journal of Biological Chemistry
(1994) - et al.
The amyloid precursor protein intracellular domain (AICD) as modulator of gene expression, apoptosis, and cytoskeletal dynamics-relevance for Alzheimer's disease
Progress in Neurobiology
(2008) - et al.
Transgenic mice expressing APP-C100 in the brain
Neurobiology of Aging
(1996) - et al.
Presenilin-dependent transcriptional control of the Abeta-degrading enzyme neprilysin by intracellular domains of betaAPP and APLP
Neuron
(2005) Multiple targets for brefeldin A
Cell
(1991)- et al.
Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation
Journal of Biological Chemistry
(1998)
X11 interaction with beta-amyloid precursor protein modulates its cellular stabilization and reduces amyloid beta-protein secretion
Journal of Biological Chemistry
Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration
Neuron
Expression of Alzheimer's disease-associated presenilin-1 is controlled by proteolytic degradation and complex formation
Journal of Biological Chemistry
Regulation of amyloid beta-protein precursor by phosphorylation and protein interactions
Journal of Biological Chemistry
Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology
American Journal of Pathology
Clearance of Alzheimer's Abeta peptide: the many roads to perdition
Neuron
Amyloid precursor protein trafficking, processing, and function
Journal of Biological Chemistry
Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory
Progress in Neurobiology
Deciphering the molecular basis of memory failure in Alzheimer's disease
Neuron
The cell biology of Alzheimer's disease: uncovering the secrets of secretases
Current Opinion in Neurobiology
The profile of soluble amyloid beta protein in cultured cell media. Detection and quantification of amyloid beta protein and variants by immunoprecipitation-mass spectrometry
Journal of Biological Chemistry
Identification of a new presenilin-dependent ζ-cleavage site within the transmembrane domain of amyloid precursor protein
Journal of Biological Chemistry
Cited by (6)
Troubleshooting pharmacological and toxicological methods
2010, Journal of Pharmacological and Toxicological MethodsCyclopentanone derivative attenuates memory impairment by inhibiting amyloid plaques formation in the 5xfad mice
2021, International Journal of Molecular SciencesPresenilin controls kinesin-1 and dynein function during APP-vesicle transport in vivo
2013, Human Molecular GeneticsIntraneuronal β-amyloid accumulation and synapse pathology in Alzheimer's disease
2010, Acta Neuropathologica